LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Human Intestinal Enteroids Used to Detect Norovirus Infectivity

By LabMedica International staff writers
Posted on 12 Sep 2019
Print article
Image: The RIDAQUICK Norovirus test is a quick qualitative immunochromatographic test for determining genogroup 1 (GG I) and genogroup 2 (GG II) noroviruses in stool samples (Photo courtesy of R-Biopharm AG).
Image: The RIDAQUICK Norovirus test is a quick qualitative immunochromatographic test for determining genogroup 1 (GG I) and genogroup 2 (GG II) noroviruses in stool samples (Photo courtesy of R-Biopharm AG).
Human norovirus accounts for 18% of acute gastroenteritis cases worldwide. Molecular nucleic acid tests, such as real-time reverse transcription polymerase chain reaction (rRT-PCR), are widely used for laboratory diagnosis of norovirus RNA in clinical samples.

These molecular assays are virus specific and their analytical sensitivity is high, but they cannot distinguish between infectious and noninfectious viruses. A recently developed human intestinal enteroid (HIE) culture system (cultures that contain multiple intestinal epithelial cell types) for human norovirus correlates between viral load and virus infectivity.

Scientists at the Chinese University of Hong Kong (Hong Kong, China) examined the infectivity of human pandemic norovirus genogroup II genotype 4 (GII.Pe-GII.4 Sydney) strains at different inoculating levels by using the adult stem cell–derived HIE line J2. The team used fecal samples from three norovirus-positive children and from adults in the norovirus surveillance program in Hong Kong.

The investigators measured norovirus RNA levels in supernatant at 1, 24, and 72 hours after inoculation by using rRT-PCR with a 10-fold serially diluted standard of in vitro–transcribed norovirus RNA. They considered a >10-fold increase in RNA level at 72 hours after inoculation from baseline (1 hour after inoculation) to indicate productive viral replication and to confirm the presence of infectious virus. They subjected fecal filtrate dilutions to norovirus antigen detection by use of the commercial RIDASCREEN Norovirus 3rd Generation EIA.

The team reported that from 2014 through 2018, a total of 114 (6.5%) of 1,754 norovirus-positive fecal samples from patients admitted to the Prince of Wales Hospital, with acute gastroenteritis had Ct values >30 (Ct median 17.8; interquartile range 14.8–22.3; range 5.5–39.2). Among the 1,579 (90.0%) genotyped samples, the proportion of GII.4 was 49.1%; other GII, 44.8%; GI, 5.2%; and co-infections with >1 norovirus capsid genotype, 0.9%. Analytical sensitivity of virus replication in HIEs for measuring moderate norovirus shedding was higher than that of EIA by being able to detect infectious virus in fecal filtrate dilutions with Ct values of 25–30.

The authors concluded that they had demonstrated that a Ct cutoff of 30 for a widely used clinical diagnostic rRT-PCR can indicate the presence of infectious GII.Pe-GII.4 Sydney norovirus in an HIE culture model. Patients shedding low levels of norovirus RNA may not be infectious, which should be considered both for estimation of attributable norovirus burden and for clinical management of viral gastroenteritis. The study was published in the September 2019 issue of the journal Emerging Infectious Diseases.

Related Links:
Chinese University of Hong Kong

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.